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Gamma-glutamyltransferase (γ-GT; EC
2.3.2.2) is the sole enzyme activity capa-
ble of cleaving the gamma-glutamyl bond
present in the structure of glutathione
(GSH), the well known antioxidant tripep-
tide, and is present on the outer aspect of
plasma membranes of virtually all mam-
malian cells. γ-GT–mediated cleavage is
the first step in the degradation of extra-
cellular GSH, which proceeds by the action
of dipeptidases and makes thus precur-
sor aminoacids (cysteine in the first place)
available for reuptake and re-utilization by
the cell for GSH resynthesis. On the other
hand, γ-GT is also responsible for the pro-
cessing of other substrates including GSH
in their structure, such as major inflam-
matory mediators leukotriene C4 (LTC4)
and S-nitroso-glutathione (GSNO), as
well as adducts of GSH with xenobiotics
and metabolites formed by the action of
glutathione-S-transferases.
Due to its critical role in cellular GSH
resupply, γ-GT has long been consid-
ered as just a part of cellular antioxidant
defenses. However, prooxidant effects of
γ-GT were also documented (Dominici
et al., 2005), and the significance of
this enzyme activity in cellular phys-
iology and medicine has considerably
expanded as its central role in modula-
tion of overall redox equilibria of the cell
has become increasingly clear. In their
book “Gamma-Glutamyl Transpeptidases:
Structure and Function” (Castellano and
Merlino, 2013) the authors provide a com-
prehensive coverage of the state-of-art
knowledge on many relevant aspects of the
matter. After a brief general introduction,
Chapter 2 provides an updated overview
of the complex γ-GT gene structure, as
well as of expression, induction and dis-
tribution of the enzyme in mammalian
tissues. The following chapters are con-
cerned with structure-function correlates,
and start with an interesting section on
the enzyme “autoprocessing,” i.e., the pro-
cess by which precursor γ-GT protein—
translated as a single polypeptide—exerts
a proteolytic cleavage on its own structure
thus yielding a large and a small subunits
which then assemble together to give the
mature enzyme dimer. To date structural
characterization of human γ-GT1 (hGT1)
has been hampered by its heavily glyco-
sylated structure, as well as by its associ-
ation with cell membranes, and most of
the knowledge regarding enzyme struc-
ture indeed comes from investigations in
bacteria. The text analyzes in detail the
characteristics of enzyme active site and
factors affecting substrate binding affin-
ity, the reaction mechanism and its steps,
the mechanisms of enzyme inhibition by
several distinct compounds, the assays
available to measure enzyme activity, the
biochemical characteristics of the enzyme
protein, etc. This part—Chapters 3 and
4—form the core of the book, in which the
authors directly capitalize the competences
developed in their own laboratory.
Nevertheless, the text is forcedly lack-
ing an important aspect of the matter, i.e.
the recently published characterization of
macromolecular complexes carrying γ-GT
in biological fluids. It has been in fact doc-
umented that γ-GT associates in plasma
with macromolecular carriers having dif-
ferent molecular weights, densities and
charges, and recently four distinct γ-GT
fractions were identified (Franzini et al.,
2013). A first characterization has shown
that the “b-GGT” fraction consists of
membrane microvesicles resembling exo-
somes (Fornaciari et al., 2014). Additional
insights into hGT1 high-resolution crystal
structure have also been recently reported
(West et al., 2013), highlighting specific
differences between bacterial and human
architectures.
A better knowledge of γ-GT struc-
ture will undoubtly help to clarify its
interactions with carriers and improve its
clinical value and specificity as a dis-
ease biomarker. Chapter 5 (“γ-GT in
Bioclinical”) indeed provides an overview
of the pathophysiological roles played
by γ-GT in human pathology. In clin-
ical medicine, γ-GT plasma levels are
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considered a well established and sensi-
tive index of hepato-biliary disease and
alcohol abuse, but during the last decade
the involvement of γ-GT in other impor-
tant diseases has also been documented.
A series of large-scale, prospective stud-
ies have shown that plasma γ-GT values
are independent predictors of cardiovascu-
lar mortality, stroke, metabolic syndrome
and diabetes, which appears to confirm the
involvement of γ-GT in mechanisms of
flogosis and cellular damage. Expression of
γ-GT during cancer progression is a factor
in drug resistance of cancer cells, e.g., to
cisplatin. This part however is a less inter-
esting section of the book, as the same top-
ics were previously discussed in detail by
others (Pompella et al., 2007; Corti et al.,
2010).
The final Chapter 6 includes an accu-
rate and compelling overview to the
biotechnological and biomedical appli-
cations of γ-GT, exploiting the unique
capability of this enzyme to cleave the
gamma-glutamyl bond. For this reason,
e.g., the addition of a gamma-glutamyl
group to a drug molecule can make it
inactive until the moment the residue
is cleaved off by γ-GT. The examples
described include the synthesis of gamma-
D-glutamyl-L-tryptophan (a compound
employed for treatment of tuberculo-
sis) and phenylhydrazine derivatives,
exhibiting antioxidant and immunos-
timulatory properties. The use of γ-GT
from Bacillus subtilis—which can act as
cephalosporin acylase—in the produc-
tion of cephalosporins, and the possible
use of γ-GT in the production of thea-
nine are also discussed. The Authors
might have as well cited the recent
development of the GSH-containing
arsenic trioxide–based pro-drug 4-(N-(S-
glutathionylacetyl)amino)phenylarsinous
acid (GSAO), which is selectively activated
by γ-GT expressed by cancer cells and
exerts a remarkable anti-angiogenic effect
(Dilda et al., 2008).
In summary, the book by Castellano
and Merlino covers a full spectrum of rele-
vant topics regarding γ-GT biochemistry,
pathophysiology and biotechnology. This
concise text—integrated by a combination
of comprehensive and useful tables, fig-
ures, and graphs reporting essential infor-
mation in a clear and detailed way—
can provide a precious introduction to
γ-GT, a complex and rapidly developing
field of interest for a wide readership of
biochemists, biologists, and clinicians.
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